{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-034121","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2023-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.840302+00:00","generated_at":"2026-06-13T09:30:59.907680+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AVROBIO halts gene therapy programs, cuts 50% workforce, explores strategic alternatives","bullets":["Board approved halting all program development; workforce reduction of ~50% expected by end of July 2023.","Estimated severance and termination costs total ~$2.8 million, to be recorded in Q3 2023.","Company to explore strategic alternatives including acquisition, merger, or business combination.","Decision not related to safety or regulatory issues; remaining staff to focus on strategic alternatives and Novartis services.","No timetable for completion; no assurance any transaction will occur."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-034121","json":"https://secwatch.observer/filing/0001140361-23-034121.json","markdown":"https://secwatch.observer/filing/0001140361-23-034121.md","text":"https://secwatch.observer/filing/0001140361-23-034121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123034121/0001140361-23-034121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123034121/brhc20055746_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:30:59.907680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01f9b5efd0896d94bc0ca4b26c2f5e4ca9f21c4f","claim":"Tectonic Therapeutic, Inc. announced a restructuring with charges of approximately $2.8 million (approximately 50%).","evidence_excerpt":"Reduction will be offered separation benefits, including severance payments. The Company estimates that the severance and termination-related costs will total approximately $2.8 million in the aggregate and expects to primarily record these charges in the third quarter of 2023. The Company expects that payments of these costs will substantially be made through","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123034121/0001140361-23-034121-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.8 million"},{"label":"Headcount","value":"approximately 50%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}